Analysts expect that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.47) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.38). Syros Pharmaceuticals reported earnings per share of ($0.54) in the same quarter last year, which suggests a positive year-over-year growth rate of 13%. The company is scheduled to report its next earnings report on Thursday, March 5th.
On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.88) per share for the current financial year, with EPS estimates ranging from ($2.01) to ($1.77). For the next financial year, analysts anticipate that the company will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.38) to ($1.56). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.01. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.43 million.
Several equities analysts have weighed in on SYRS shares. ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. BidaskClub downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 15th. JMP Securities lowered their price target on shares of Syros Pharmaceuticals from $18.00 to $16.00 and set a “market outperform” rating on the stock in a report on Friday, October 18th. Finally, Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $12.89.
Several hedge funds have recently added to or reduced their stakes in SYRS. Tower Research Capital LLC TRC increased its position in Syros Pharmaceuticals by 863.4% in the third quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock worth $28,000 after purchasing an additional 2,409 shares during the last quarter. Bank of Montreal Can increased its position in Syros Pharmaceuticals by 44.6% in the fourth quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock worth $30,000 after purchasing an additional 1,357 shares during the last quarter. Citigroup Inc. increased its position in Syros Pharmaceuticals by 175.0% in the fourth quarter. Citigroup Inc. now owns 10,236 shares of the company’s stock worth $71,000 after purchasing an additional 6,514 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Syros Pharmaceuticals in the fourth quarter worth $77,000. Finally, Trexquant Investment LP bought a new stake in Syros Pharmaceuticals in the fourth quarter worth $92,000.
NASDAQ:SYRS traded up $0.33 during trading hours on Friday, hitting $7.87. 111,000 shares of the stock traded hands, compared to its average volume of 249,803. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.20. Syros Pharmaceuticals has a 1 year low of $4.45 and a 1 year high of $11.93. The company has a market cap of $320.43 million, a price-to-earnings ratio of -3.99 and a beta of 1.58. The stock has a 50 day moving average price of $7.53 and a 200 day moving average price of $7.68.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Recommended Story: P/E Growth (PEG)
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.